MedTrace Logo

DHA Supplementation and Pregnancy Outcome

NCT00266825 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2016-03-14

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.

Conditions

  • Pregnancy

Interventions

DRUG

DHA

600 mg DHA

OTHER

Placebo capsule

Placebo capsule

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • Susan Carlson, PhD

    lead OTHER

Principal Investigators

  • Susan E Carlson, PhD · University of Kansas Medical Center

  • John Colombo, PhD · University of Kansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
36 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00266825 on ClinicalTrials.gov